Navigation Links
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Date:3/24/2008

Potential NDA Submission in 2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today that enrollment is complete in the phase III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL). An analysis of the data is expected in the second half of 2008. Based on prior discussions with the U.S. Food and Drug Administration (FDA) the data could provide a registration path for pixantrone if final study results are adequate for submitting a New Drug Application (NDA) with the FDA in early 2009 with a potential approval in 2009. A total of 140 patients were enrolled in the study, 97 patients are currently evaluable according to Histological Intent to Treat, or HITT, criteria and will be included in the final analysis of the study.

"PIX301 examines the effectiveness of pixantrone in patients with relapsed and refractory diffuse large B cell lymphoma, a population where current therapies seldom induce complete remissions," said Jack W. Singer, Chief Medical Officer at CTI. "Based on a blinded current independent assessment of events in the trial we believe we have an adequate sample size of eligible patients to meet the primary objective of the trial."

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantrone or another single-agent drug currently used
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
11. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , CENTENNIAL, Colo., Dec. 2 /PRNewswire/...ofit providers of skin, bone and soft tissue allog...,s largest processor of live cellular bone growth ...truly iconic symbol of hope as a float rider aboar...010 Tournament of Roses Parade®. Manuel Sala...
(Date:12/2/2009)..., , DUBLIN, Ohio, Dec. 2 /PRNewswire-FirstC...e Cox will serve on the company,s board of directo...ently served as executive vice president and presi...Corp. She completed her tenure with the company at..., Prior to her term at Schering-Plough, Cox ser...
(Date:12/2/2009)..., , ROCKVILLE, Md., Dec. 2 /PRNewswire-Fir...ported favorable initial results from the first st...ng the safety and immunogenicity of the company,s ...enza vaccine. Novavax is conducting this study in...to support registration of the vaccine in Mexico a...
Breaking Medicine Technology:AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3Cardinal Health Names Carrie Cox to Board of Directors 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 14644 1Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA 14642 1Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA 14642 2Alexandria Real Estate Equities Inc Provides Update 14640 1Alexandria Real Estate Equities Inc Provides Update 14640 2Alexandria Real Estate Equities Inc Provides Update 14640 3Alexandria Real Estate Equities Inc Provides Update 14640 4
...ESS WIRE)--May 17, 2007 - Salix,Pharmaceuticals, L...18 investigator-initiated trials related to the Co...sease Week(R) 2007, which will be,held May 19-24, ...gest and most prestigious meeting in the world for...than 16,000 physicians,researchers and academics ...
...nted at Society for Investigative Dermatology, FRE...atics,recently announced new comparative clinical ...e ability to recognize, transport and,utilize L-er...,damage, and importantly, that (EGT) acts as a mor...e, scavenging reactive oxygen,species and reducing...
Other Medicine Technology:Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage 2
(Date:12/2/2009)... incidence of obesity could counter recent increas...ealthDay News) -- The overall health of the U.S. p..., largely because people have quit smoking in drov...n be wiped out if the rising obesity rates among A...trends in both smoking and obesity continue unchan...
(Date:12/2/2009)...prolongs life remains unclear, researchers say , ...ew research suggests that enzyme replacement thera...ple with Fabry disease, a rare illness that affect...ive disease, linked to the lack of an enzyme that ... be fatal because it boosts the risk for a stroke,...
(Date:12/2/2009)...NIA BEACH, Va., Dec. 2 By now, mos...eless cigarettes continue to grow in popularity. A...ble at the PremiumEcigarette - the new single piec... at the amazingly low price of $14.99. ,, "This...he e-cigarette at a very low price, before making ...
(Date:12/2/2009)... , New Directors Represent Diverse Healthcar...wire-USNewswire/ -- The membership of the National...ts Board of Directors and reappointed four current...wide range of healthcare stakeholders, including c... public and community healthcare. ,, The newly...
(Date:12/2/2009)...DELPHIA, Dec. 2 Independence Blue ...s contract with Lincoln Financial Group. IBC will ...proximately 10,000 Lincoln Financial Group employe...on. The Lincoln plan offerings will include the PP..., "I know I speak for all of us at Independence ...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3
...chers at the University of Pennsylvania School of ...l cargo in nerve cells react differently when expo...ole in Alzheimers disease. , Dynein and kinesin ... to regulate protein traffic, the group found. But...
... Following is a,media statement attributable to B...ersey Hospital Association:, "NJHA applauds the s...ty Initiative report. This is a valuable document ...efforts. The confidential reporting and,collaborat...
...7 Immunosyn,Corporation (OTC Bulletin Board: IMYN... "Proof of Concept Trial" for the biopharmaceutica...e for treatment of Diabetic Ulcers., The Board of...and largest shareholder. Argyll Biotechnologies is...
...lished in the January 18 edition (Volume 28, Issue...ing action is the result of what is known as a non...uired for the development of the disease. A nonsen...work of protein fibers or filaments in the cell th...
...12 expected this spring, officials add , ,...ood and Drug Administration on Thursday issued a p...r cough and cold medicines should not be given to ... recent months, FDA officials said they were conce...
...ers a safe effective, and inexpensive alternative ...., BERKELEY SPRINGS, W.Va., Jan. 17 The US Food ...ugh and cold medicine is too risky,for babies and ...fe threatening side effects of cold and cough medi...
Other Medicine News:Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 3Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 2Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 3Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 4Health News:FDA to Declare Cold Medicines Too Risky, Homeopathy Offers a Safe Alternative 2
Anti-Mumps IgG Assay
...tech Captia™ Mumps IgG Enzyme- linked Immunoso...and quantitative determination of IgG antibody to ...ens may be used for the determination of immune st...used to demonstrate seroconversion or a significan...
Mumps IgM ELISA
Mumps IgG ELISA
Medicine Products: